An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.

Trial Profile

An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Tenofovir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Actual patient number changed from 25 to 30 as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Planned end date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top